- Home
- PRLD vs PMVP Comparison
PRLD vs PMVP Comparison
Compare PRLD & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRLD
- PMVP
- Stock Information
- Founded
- PRLD 2016
- PMVP 2013
- Country
- PRLD United States
- PMVP United States
- Employees
- PRLD N/A
- PMVP N/A
- Industry
- PRLD Medicinal Chemicals and Botanical Products
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- PRLD Health Care
- PMVP Health Care
- Exchange
- PRLD Nasdaq
- PMVP Nasdaq
- Market Cap
- PRLD 69.1M
- PMVP 76.8M
- IPO Year
- PRLD 2020
- PMVP 2020
- Fundamental
- Price
- PRLD $1.42
- PMVP $1.42
- Analyst Decision
- PRLD Strong Buy
- PMVP Strong Buy
- Analyst Count
- PRLD 3
- PMVP 1
- Target Price
- PRLD $4.00
- PMVP $5.00
- AVG Volume (30 Days)
- PRLD 290.5K
- PMVP 949.9K
- Earning Date
- PRLD 11-05-2025
- PMVP 11-06-2025
- Dividend Yield
- PRLD N/A
- PMVP N/A
- EPS Growth
- PRLD N/A
- PMVP N/A
- EPS
- PRLD N/A
- PMVP N/A
- Revenue
- PRLD $7,000,000.00
- PMVP N/A
- Revenue This Year
- PRLD N/A
- PMVP N/A
- Revenue Next Year
- PRLD N/A
- PMVP N/A
- P/E Ratio
- PRLD N/A
- PMVP N/A
- Revenue Growth
- PRLD N/A
- PMVP N/A
- 52 Week Low
- PRLD $0.61
- PMVP $0.81
- 52 Week High
- PRLD $2.08
- PMVP $1.84
- Technical
- Relative Strength Index (RSI)
- PRLD 60.29
- PMVP 50.54
- Support Level
- PRLD $1.33
- PMVP $1.36
- Resistance Level
- PRLD $1.63
- PMVP $1.49
- Average True Range (ATR)
- PRLD 0.18
- PMVP 0.08
- MACD
- PRLD 0.01
- PMVP 0.01
- Stochastic Oscillator
- PRLD 49.42
- PMVP 57.41
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.